ClinicalTrials.gg
RecruitingNCT07047235STRATA-AFUpdated Nov 19, 2026

Substrate Remodelling and Targeted Ablation in AF

An interventional study of Pulmonary vein reisolation and Ganglionic plexi ablation in Atrial Fibrillation (AF), Atrial Fibrillation Mechanisms and Catheter Ablation, sponsored by Barts & The London NHS Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Barts & The London NHS Trust · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
160
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Atrial Fibrillation by Barts & The London NHS Trust — 6 open to participants now, 6 under way, none of them phase 3. Atrial Fibrillation · Barts & The London NHS Trust.

Planned enrollment
6th of 20
160 · median 104
Started
2025
the only one that year
No phase
15 of 23
4 open now
Registered
22nd of 23
by date

Among the 23 studies in Atrial Fibrillation by Barts & The London NHS Trust, this one is the 6th largest by planned enrollment of the 20 interventional ones that give a count, is the only one that started in 2025, is one of 15 with no phase, and was the 22nd registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

6 of the 23 studies in Atrial Fibrillation by Barts & The London NHS Trust are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Atrial Fibrillation by Barts & The London NHS Trust, or all of them as a file.
02

Study summary

Atrial fibrillation (AF) is the most common heart rhythm disorder, affecting millions worldwide and causing symptoms such as palpitations, fatigue and breathlessness. It also increases the risk of stroke and heart failure, so effective treatment is essential.

A treatment for AF involves catheter ablation, a minimally invasive procedure where problematic areas of the heart are targeted using controlled energy. This is done by passing wires called catheters, through blood vessels at the top of the leg all the way to the heart. However, this isn't effective for everyone and approximately half of patients experience a return of AF despite treatment.

In this researcher-led study at St Bartholomew's Hospital , the investigators will use a method called electroanatomical mapping to make a 3D picture of the left atrium, the heart's upper left chamber. To make this picture more detailed, information will be collected - such as how strong electrical signals are (voltage), how fast and in which direction they travel through the heart to describe abnormal areas and areas of scar within the heart. Information will also be gathered about the routes electricity takes and the nerve activity in the heart muscle. These detailed maps will help to understand why AF can continue indefinitely in some people, why ablation works for some people and not others, and improve how ablations are done to make them more effective.

All participants will undergo catheter ablation with these mapping methods integrated into the procedure. If AF recurs, patients will be invited for a second ablation targeting specific abnormal areas depending on the amount of scar found. This will be standardised across patients.

Patients will be followed for 12 months, with structured visits at 3, 6, 9 and 12 months and 48-hour ECG recorders at 6 and 12 months. By tracking how the heart's structure and electrical behaviour evolve, the aim is to to see if map-guided ablation reduces the need for further procedures, lowers healthcare costs and improves quality of life.

Ultimately, this study will provide clear, reproducible insights into AF mechanisms and yield practical guidance so clinicians can predict who will benefit from standard ablation treatment and who may require extra, map-guided treatment.

03

Conditions studied

  • Atrial Fibrillation (AF)
  • Atrial Fibrillation Mechanisms
  • Catheter Ablation
  • Low Voltage Areas

Browse trials for

Keywords

  • ganglionic plexi
  • autonomic remodelling
  • substrate remodelling
  • conduction velocity
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able and willing to provide written
  • Age: 18 years or older
  • Clinical diagnosis: Persistent atrial fibrillation
  • Treatment status: Scheduled to undergo first-time catheter ablation for persistent AF

Exclusion criteria

Exclusion Criteria:

  • Inability or unwillingness to provide
  • Under 18 years of age
  • Previous left atrial ablation for AF or other atrial arrhythmias
  • Any clinical to undergoing AF catheter ablation
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
160 participants (estimated)

Study arms

  • Active comparator
    Minimal Low Voltage Zones Group

    These are patients who've had recurrence of AF after their first ablation and less than 30% of their atria is comprised of low voltage zones. They will undergo autonomic ganglionic plexi site ablation combined with pulmonary vein re-isolation.

    Procedure: Pulmonary vein reisolation · Procedure: Ganglionic plexi ablation

  • Active comparator
    Significant Low Voltage Zones Group

    These are patients who've had recurrence of AF after their first ablation and greater than 30% of their atria is comprised of low voltage zones. They will undergo targeted ablation of conduction slowing sites in addition to ganlionic plexi site ablation and pulmonary vein reisolation.

    Procedure: Pulmonary vein reisolation · Procedure: Ganglionic plexi ablation · Procedure: Substrate ablation

Interventions

  • ProcedurePulmonary vein reisolation

    The pulmonary veins will be checked electrically and further ablation will be undertaken if they are not isolated.

  • ProcedureGanglionic plexi ablation

    Sites where ganglionix plexi have been found will be ablated.

  • ProcedureSubstrate ablation

    Areas of rate dependent conduction velocity slowing will be targeted using cathether ablation

06

What researchers measure

Primary outcomes

  1. Assessment of Electrical, Structural and Autonomic Remodelling in Persistent Atrial Fibrillation

    A primary objective of this study is to delineate the remodelling changes that occur in persistent atrial fibrillation and to utilise these to develop tailored ablation strategies.

    Time frame: 4 years

  2. Establish a Predictive Model to Idenitfy Which Patients are Responders to Pulmonary Vein Isolation Alone and Who Will Require Further Tailored Ablation Strategies

    Based on clinical data approximately only 50% of patients with persistent atrial fibrillation who undergo pulmonary vein isolation remain in sinus rhythm. A main aim of the study is to develop a method to identify which patients will respond to pulmonary vein isolation alone and who will require further tailored ablation strategies.

    Time frame: 24 months

  3. To Assess if Ablation of Rate Dependent Conduction Velocity Slowing Sites Improves Freedom from Atrial Fibrillation

    All patients who recur after their initial ablation will be invited to undergo a repeat ablation procedure. All patients will undergo ganglionic plexi ablation and reisolation their pulmonary veins. Those who have low voltage zones of more than 30% of their total left atrium will undergo further ablation of rate dependent conduction velocity slowing sites.

    Time frame: 5 years

Secondary outcomes

  1. Develop Personalised Electrical Atrial Models

    The data taken from the electrophysiological procedures will be used to create mathematical computer models that can be used as an environment to test electrophysiological theories and response to ablation.

    Time frame: 5 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Nov 2029, 48 months after the start.

Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 48 months is above that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2025
First posted
Jul 2, 2025
StartActual
Nov 7, 2025
Primary completionEst.
Nov 18, 2029
CompletionEst.
Aug 18, 2030
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07047235
Responsible party
Sponsor
First posted
Jul 2, 2025
Start date
Nov 7, 2025
Primary completion
Nov 18, 2029 (estimated)
Completion
Aug 18, 2030 (estimated)
Last update
Nov 19, 2026

Study contacts

Shohreh Honarbakhsh, MBBS, MRCP, PhD
Contact
shohreh.honarbakhsh@nhs.net
02037658682
Sayed Al-Aidarous, MBBS, MRCP
Contact
sayed.al-aidarous@nhs.net

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion